Share on StockTwits

InterMune (NASDAQ:ITMN) EVP Andrew Kenneth William Powell unloaded 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.47, for a total transaction of $551,025.00. Following the completion of the transaction, the executive vice president now directly owns 30,927 shares in the company, valued at approximately $2,272,207. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of research firms have recently commented on ITMN. Analysts at RBC Capital raised their price target on shares of InterMune from $44.00 to $74.00 in a research note on Friday, August 29th. Separately, analysts at Cowen and Company initiated coverage on shares of InterMune in a research note on Thursday, August 28th. They set a “market perform” rating and a $74.00 price target on the stock. Finally, analysts at JMP Securities downgraded shares of InterMune from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 26th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. InterMune currently has an average rating of “Hold” and a consensus target price of $63.08.

InterMune (NASDAQ:ITMN) traded down 0.07% on Wednesday, hitting $73.435. The stock had a trading volume of 2,712,573 shares. InterMune has a 1-year low of $10.95 and a 1-year high of $73.52. The stock’s 50-day moving average is $51.16 and its 200-day moving average is $39.28. The company’s market cap is $7.929 billion.

InterMune (NASDAQ:ITMN) last announced its earnings results on Wednesday, August 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the previous year, the company posted ($0.77) earnings per share. The company’s revenue for the quarter was up 141.2% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.72 earnings per share for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Receive News & Ratings for InterMune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterMune Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.